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BMI Trajectories from Birth to 23 Years by 
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Objective: The aim of this study was to investigate whether the level, 
rate, and acceleration of BMI growth differ according to the presence 
or absence of adult cardiometabolic (CM) risks.
Methods: BMI was measured in 1,000 Chileans at nine time points 
from birth to 23 years, and metabolic syndrome and its components 
were assessed at young adulthood. BMI growth was analyzed in the 
following three developmental periods: birth to 6 months, 6 months to 
5 years, and 5 to 23 years.
Results: Individuals with CM risks had a specific constellation of early-
life growth (faster growth after infancy, lower BMI decline approaching 
age 5, absence of a definitive BMI nadir in early childhood, higher 
5-year BMI) and distinct young adult growth (larger BMI increases from 
childhood to young adulthood and lower levels of expected growth 
deceleration approaching young adulthood). Those with CM risks 
also attained BMI ≥ 25 at significantly younger ages than those absent 
risks (metabolic syndrome: 12.3 years vs. 20.1 years; hyperglycemia: 
13.1 years vs. 18.9 years; hypertension: 13.2 years vs. 19.4 years; 
hypertriglyceridemia: 14.3 years vs. 19.5 years; inflammation: 
15.9 years vs. 20.6 years).
Conclusions: Larger and faster increases in BMI and a failure of BMI 
growth to decline or decelerate at specific developmental periods dis-
tinguished individuals who would and would not have adult CM risks.
Obesity (2020) 28, 813-821. 
Introduction
Obesity during childhood is a known risk factor for poor adult cardiometabolic (CM) 
functioning (1,2). Recently, BMI growth trajectories have been examined in relation to 
cardiovascular health. These studies generally have linked specific BMI growth patterns to 
later CM risks (3-7) or evaluated how age-specific changes in BMI relate to cardiovascular 
disease (7-9). However, longitudinal studies in which both BMI growth patterns and adult 
CM disease are known can also be useful for understanding how growth patterns differ 
according to the presence or absence of CM risks. A few studies have used this approach. 
Giudici et al. (10) found that higher parent-reported child BMI from age 4 to 10 years 
distinguished those who had metabolic syndrome (MetS) at 20 to 60 years of age. Fall 
et al. (11) found that those with MetS at ages 26 to 32 years had greater BMI gain from 
infancy to adolescence than those not having MetS. Although such studies have adopted 
an interesting approach of contrasting growth patterns by known CM risk, neither study 
compared the rate of BMI change or possible BMI growth acceleration or deceleration by 
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What is already known?
►	Large increases in body mass and over-
weight/obesity relate to poor cardiometa-
bolic outcomes.
What does this study add?
►	This study analyzed body mass at nine time 
points from birth to age 23 years in 1,000 
Chileans and found that individuals with 
adult cardiometabolic risks had a specific 
constellation of early-life growth (faster 
growth after infancy, lower body mass de-
cline approaching age 5, absence of a de-
finitive body mass nadir in early childhood, 
higher 5-year body mass) and a distinct 
midlife growth pattern (larger body mass in-
creases from childhood to young adulthood 
and lower levels of expected growth decel-
eration approaching young adulthood).
►	Larger and faster increases in BMI and a 
failure of BMI growth to decline or deceler-
ate at specific developmental periods differ-
entiated individuals who would and would 
not have adult cardiometabolic risks.
How might these results change the 
direction of research?
►	These findings call for further understand-
ing of discernible patterns of BMI growth 
across development, from birth to young 
adulthood, that precede cardiometabolic 
risks.
►	Obesity interventions implemented from in-
fancy to late adolescence may be effective 
for reducing cardiometabolic risks.
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subsequent CM risk. Yet larger and faster BMI increases have been asso-
ciated with poorer CM outcomes (7,9,12). Thus, comparing BMI growth, 
as well as BMI at various ages, by subsequent CM risk allows one to not 
only determine whether distinct growth patterns precede CM risk, but also 
to quantify how such growth patterns might diverge.
This study investigated whether the level, rate, and acceleration of BMI 
growth from birth to age 23 years differ according to the presence or 
absence of CM risk factors in young adulthood. We also examined the 
age at which BMI first diverged by the presence or absence of CM risks 
and the age at which BMI ≥ 25 and BMI ≥ 30 for those with and without 
specific CM risks. CM risks studied were MetS and its components 
(hyperglycemia, hypertriglyceridemia [high triglycerides,  TG], low 
high-density lipoprotein cholesterol [HDL-C], hypertension, abdomi-
nal obesity) and inflammation (elevated C-reactive protein [CRP]).
Methods
Sample and study design
Data are from 1,000 participants of the Santiago Longitudinal Study, 
which initially involved 1,790 Chilean infants in an iron-deficiency 
anemia preventive trial and neurological maturation study (13). Infants 
were recruited at 6 months (1991-1996) from community clinics serving 
low- to middle-income families. Eligible infants were healthy full-term 
singletons with birth weight ≥ 3,000 g. The preventive trial involved ran-
dom assignment of 1,657 nonanemic infants to receive an iron-fortified 
formula (12 mg/L, comparable to the level of iron in infant formulas 
available in the United States), a low iron-fortified formula (2.3 mg/L), 
or a no–added iron formula (13). An additional 133 infants participated 
in a neurological maturation study, involving laboratory assessments in 
addition to core components of the Santiago Longitudinal Study. Weight 
and height (length) (converted to BMI in kilograms per meter squared) 
were measured at birth, 3 months, 6 months, 1 year, 5 years, 10 years, 21 
years, and 23 years as well as up to three times in adolescence (between 
11 and 18 years; mean = 15.3 years). For participants assessed more than 
once during adolescence, height and weight from the assessment closest 
to age 15 years were used, excluding those < 14 years (n = 52) or > 16 
years (n = 123). CM risk biomarkers were measured in 1,040 partici-
pants at age 23 years. Analyses utilized data from the 1,000 participants 
who had risk biomarker data at young adulthood and BMI at six or more 
time points (i.e., missing no more than three BMI values) (14). This 
criterion was based on having adequate data coverage on all variables in 
tandem with randomly distributed missingness (14). Of the participants 
who had CM biomarker data at young adulthood, > 99% had BMI data 
at birth, 3 months, 6 months, 1 year, and 23 years. However, a substantial 
budget cut at the 5-year follow-up necessitated that the low-iron supple-
mentation group (n = 405) as part of the infancy preventive trial was not 
studied. In order to maximize use of the available age 5 data, we em-
ployed the threshold requiring participants to have at least six complete 
BMI time points. This allowed us to utilize 69.1% of the data collected 
at age 5 and a minimum of 87.6% of data collected at the other time 
points (Table 1). These are deemed acceptable levels of missing data 
when data are assumed to be missing completely at random (14,15). The 
missing completely at random test provided evidence that data within 
the current analytic sample were missing completely at random (Little’s 
χ2 [df = 77] 90.33; P = 0.134) (15). Sample follow-up and loss at each 
study time point are shown in Supporting Information Figure S1).
Characteristics of the sample (duration of breastfeeding, mothers’ age, 
socioeconomic status [SES], etc. (16)) were assessed when participants 
were age  1 year (Table 1). When children were 10 years, mothers 
self-reported their prepregnancy height and weight, from which mater-
nal BMI was calculated. Participants included in the current analyses 
were similar in background characteristics, age, and BMI at all time 
points to those not included. However, those analyzed were more likely 
to be female, from families with higher SES, and less likely to have 
received iron supplementation as part of the preventive trial (Supporting 
Information Table S1). Approval for this study was obtained from the 
authors’ institutional review boards in the United States and Chile. 
Informed written consent was obtained from children’s parents at all 
time points prior to child age 21; participants gave written informed 
consent at ages 21 and 23 years. Participants received a stipend at the 
23-year assessment. All study procedures were in accord with the Code 
of Ethics of the World Medical Association (17).
Measurements
Anthropometric assessment. Weight and length at birth and 3 months 
were abstracted from medical records. Infants’ unclothed weight at 6 
months and 1 year was measured using an electronic scale (to the nearest 
0.01 kg), and length was measured using a recumbent length board (to the 
nearest 0.1 cm) by a trained research clinician at the Institute of Nutrition 
and Food Technology at the University of Chile. At all other time points, 
standardized procedures were used at the Institute of Nutrition and Food 
Technology to measure height (centimeters) to the nearest 0.1 cm (using 
a Holtain stadiometer;  Holtain Ltd., Crosswell, Crymmich, UK) and 
weight (kilograms) to the nearest 0.1 kg (using a Seca 703 scale; Seca, 
Hamburg, Germany). Measurements at age 5 years and older were taken 
twice, with a third measurement if the difference between the first two 
exceeded 0.3 kg for weight or 0.5 cm for height. BMI was calculated 
from weight and height (kilograms per meter squared) (or weight and 
length). Raw BMI scores at all time points were used in analyses for 
consistency in estimating the trajectory. Studies support the use of raw 
BMI scores as an indicator of obesity in children (18,19) and as a useful 
measure of adiposity change in longitudinal research that involves 
children and adults (20). At the 23-year follow-up, waist circumference 
(WC) was measured with nonelastic flexible tape and recorded to 0.1 cm.
CM risk assessment. At the young adult assessment (mean age = 23.0 
years), after 15 minutes of rest, systolic and diastolic blood pressures 
were measured three times on the nondominant arm using a standard 
mercury sphygmomanometer. The first measurement was discarded, 
and the second two were averaged for analysis (21). Fasting serum 
total glucose (milligrams per deciliter), total cholesterol (milligrams 
per deciliter), TG (milligrams per deciliter), HDL-C  (milligrams 
per deciliter), and high-sensitivity CRP  (milligrams per liter) were 
measured after a 12-hour overnight fast. Serum glucose concentrations 
were measured with an enzymatic colorimetric test (Quimica Clinica 
Aplicada, Amposta, Spain). Cholesterol profile was determined by dry 
analytical methodology (Vitros; Ortho Clinical Diagnostics, Johnson & 
Johnson Inc., Raritan, New Jersey). High-sensitivity CRP was measured 
with a sensitive latex-based immunoassay, with elevated inflammation 
defined as CRP ≥ 3.0 mg/L (22). MetS was based on the 2009 consensus 
definition (23), which involves having at least three of the following five 
risk factors: abdominal obesity (WC ≥ 94 cm males; ≥ 80 cm females), 
high arterial blood pressure (systolic blood pressure  ≥ 130 mmHg or 
diastolic blood pressure ≥ 85 mmHg), high TG (TG ≥ 150 mg/dL), low 
HDL-C (< 50 and < 40 mg/dL in females and males, respectively), and 
fasting hyperglycemia (glucose  ≥ 100 mg/dL) (23). Additionally, we 
calculated a continuous score representing a composite CM risk profile 
as the sum of the five MetS risks (range: 0-5).
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Covariate selection
We selected the following covariates that could potentially confound 
the BMI-CM relationship (24): participants’ sex, maternal BMI, moth-
ers’ age at the participant’s birth, duration of breastfeeding, iron sup-
plementation as part of the preventive trial, and family SES. Covariates 
were included on the growth parameters.
Statistical analysis
Given the number and timing of BMI measurements available within 
the current study, and the expectation of a variety of nonlinear change 
patterns (25), we analyzed BMI growth within the following three de-
velopmental phases: birth to 6 months, 6 months to 5 years, and 5 to 
23 years. These age phases were based on global BMI growth curves 
that show rapid BMI growth from birth to approximately 6 months, fol-
lowed by decreases leading to a nadir at approximately 4 to 7 years and 
then by steady increasing growth to young adulthood (age 20) (26,27). 
Piecewise latent growth curve analysis was conducted in Mplus 8.2 
(Muthen & Muthen, Los Angeles, California) to estimate the BMI tra-
jectories within each age period for those with and without each CM 
risk (28). We used BMI at birth as the intercept for the initial phase, 
6-month BMI as the intercept for the second phase, and 5-year BMI as 
the intercept for the third phase. We defined the intercept for each model 
at these time points because we were interested in BMI at these ages as 
well as in the growth following these ages, that is, in the three distinct 
developmental phases we have outlined. Latent growth curve analysis 
quantifies slope (the degree of linear change in BMI) and nonlinear qua-
dratic change (change in the rate of change), with the quadratic term 
indicating accelerated growth (a speeding up of BMI increase) or decel-
erated growth (a slowing down or flattening out of BMI growth) (25). 
The time scores for the quadratic slope factor are the squared values of 
the linear time scores, and these time scores are automatically computed 
by Mplus. We used the Satorra and Bentler (29) scaled χ2 difference test 
to determine whether a model that included a quadratic term provided 
a better fit with the data than a nested model that omitted the quadratic. 
χ2 differences were calculated for each of the three age periods. The χ2 
difference test was significant for the last age period only (5-23 years). 
Thus, growth during the first two age periods was estimated by intercept 
and slope, and growth during the last phase (5-23 years) was estimated 
by intercept, slope, and quadratic. The growth terms were evaluated 
in independent regression models. Model fit was evaluated based on 
well-established recommendations (30,31), with comparative fit index 
(CFI) > 0.90, root mean square error of approximation (RMSEA) < 0.06, 
and standardized root mean square residual (SRMR) < 0.08. The CFI 
is the χ2 comparison of the target model to the baseline model (the 
model in which all the regression paths are set to zero). The RMSEA 
is the average of the residuals between the observed sample covariance 
and the expected model estimated for the population. The SRMR is 
the standardized square root of the difference between the residuals of 
the observed and predicted covariance matrix. These indices comprise 
a combination of absolute fit indices (RMSEA, SRMR), an incremental 
fit index (CFI), and a parsimony-adjusted index (RMSEA) (30,31).
To test differences in growth according to the presence or absence of CM 
risks, we estimated the growth parameters (random effects derived from 
growth models) for each participant using the full sample. We report 
the means of each of these parameters stratified by CM risk (adjusted 
for covariates). Next, we assessed associations between the presence 
of each CM risk (1 = present, 0 = absent) and each growth factor. The 
growth factors were used as continuous latent variables and analyzed as 
dependent variables in multivariable linear regression models. In each 
model, the independent variable of interest was CM risk (presence vs. 
absence), adjusting for maternal BMI, breastfeeding duration, sex, SES, 
mothers’ age, and iron supplementation. A statistically significant effect 
estimate indicates that the risk-present and risk-absent growth parame-
ters are significantly different. Data were retained for all participants 
(N = 1,000) using the full information maximum likelihood specifica-
tion, which fits the model being tested directly onto the nonmissing data 
for each participant and which has been shown to be superior to other 
TABLE 1 Sample characteristics (N = 1,000)
  n Mean or % SD
Child sex (% female) 1,000 51%  
Maternal BMI (kg/m2)a 855 28.9 5.1
Maternal age (y)b 993 26.3 6.0
Family SESc 995 27.3 6.3
Received iron supplementationd 925 63.2%  
Duration of breastfeeding (mo)e 979 3.6 3.1
Birth weight (g) 1,000 3545.34 365.76
BMI (kg/m2)f      
Birth 1,000 13.8 1.1
3 mo 997 17.5 1.4
6 mo 1,000 18.0 1.5
1 y 1,000 17.8 1.4
5 y 691 17.0 2.2
10 y 876 19.4 3.3
15 y 962 23.1 4.4
21 y 916 26.4 5.3
23 y 1,000 26.7 5.6
Cardiometabolic risks at young 
adulthood
     




Low HDL-C, < 40 mg/dL male 
and < 50 mg/dL female
1,000 59.5%  
Hypertension, SBP ≥ 130 mm Hg 
or DBP ≥ 85 mm Hg
1,000 9.3%  
Abdominal obesity, ≥ 94 cm male 
and ≥ 80 cm female
1,000 31.2%  
Metabolic syndromeg 1,000 12.2%  
Number of CM risks (%) 1,000    
0   30.2%  
1   37.7%  
2   19.9%  
3   8.8%  
4   3.1%  
5   0.3%  
Inflammation, CRP ≥ 3.0 mg/L 1,000 36.7%  
aMaternal prepregnancy BMI assessed retrospectively at child age 10.
bMaternal age at study intake.
cHigher scores reflect greater family socioeconomic disadvantage at child age 
1 (range 11-47).
dRandomly assigned to receive iron-supplemented formula at 6 to 12 months as part 
of preventive trial.
eDuration exclusively breastfed (i.e., age at first bottle).
fWe used calculated BMI scores at all time points for consistency in trajectory.
gDefined as at least three cardiometabolic risks.
SES, socioeconomic status; HDL-C, high-density lipoprotein cholesterol; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; CM, cardiometabolic; CRP, C-reactive 
proteins.
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Figure 1 BMI trajectories from birth to age 23 years by cardiometabolic risk in young adulthood, adjusted for sex, maternal BMI, maternal age, family SES, 
iron supplementation from age 6 to 12 months, and duration of breastfeeding. Dashes surrounding trajectories represent 95% CI. TG, triglycerides; HDL-C, 
high-density lipoproteins cholesterol; MetS, metabolic syndrome; CM, cardiometabolic; Gli, glucose; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; WC, waist circumference; CRP, C-reactive protein. [Color figure can be viewed at wileyonlinelibrary.com]
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missing data strategies (32). For descriptive purposes, we used SAS 
(version 9.4; SAS Institute Inc., Cary, North Carolina) mixed-effects 
modeling (with a quadratic term for age) to plot BMI trajectories per 
each CM risk (Figure 1). We performed a sensitivity analysis to assess 
bias introduced by the missing data by reestimating the growth analyses 
using data from participants who had BMI data at all nine time points 
(n = 549). We also conducted analysis of covariance to determine the 
age at which BMI first significantly diverged (P < 0.05) according to 
the presence or absence of each CM risk. We also extrapolated the ages 
at which BMI ≥ 25 and BMI ≥ 30 from known BMI values per each CM 
risk group to illustrate the disparity in age at which critical BMI mile-
stones are attained for those with or without various CM risks (33).
Results
Sample characteristics
At the 23-year follow-up, 12.2% of the sample was classified as having 
MetS and approximately 70% had at least one CM risk (Table 1). The 
prevalences of low HDL-C, abdominal obesity, and inflammation were 
quite high (59.5%, 31.2%, and 36.7%, respectively), whereas the prev-
alence of high TG (14.3%), hypertension (9.3%), and hyperglycemia 
(3.5%) were moderate to low.
Growth parameters for the total sample
The fit indices indicated that the model for each developmental 
phase fit the data (CFI: 0.951-0.986; RMSEA: 0.080-0.159; SRMR: 
0.017-0.042). The growth parameters for the total sample (Table 2) 
indicated an average BMI at birth of 13.75 and significant linear BMI 
increase from birth to 6 months (slope = 0.72). The parameters for the 
second phase (6 months-5 years) indicated an average 6-month BMI 
of 18.06, with significant linear decrease in BMI from 6 months to 5 
years (slope = −0.11). The parameters for the third phase (5-23 years) 
indicated a mean 5-year BMI of 16.98, with significant linear up-
ward growth (slope = 3.34), followed by significant deceleration 
(a slowing down) of growth when  approaching young adulthood 
(quadratic = −0.10). (Supporting Information Figure S2 shows the 
growth trajectory for the total sample.)
Growth parameters by CM risk
The growth parameters for each developmental phase by the presence 
or absence of each risk factor are shown in Table 3. At level of signif-
icance α = 0.05, our data do not provide evidence to suggest that the 
intercepts at birth varied by subsequent CM risk. However, those with 
young adult abdominal obesity had greater linear growth (a faster rise 
in BMI) from birth to 6 months than those without abdominal obesity. 
Regarding growth from 6 months to 5 years, none of the CM risks 
differed by 6-month BMI. However, the slope of BMI growth during 
this phase was significantly different by presence versus absence of 
CM risk for all risks examined, with the risk-absent trajectories hav-
ing a significant linear decrease in BMI growth, whereas the risk-pres-
ent trajectories remained largely stable (flat). The parameters for the 
period from 5 to 23 years indicated that all CM risks were associated 
with a higher BMI at age 5. Five of the seven risks studied were also 
associated with greater linear growth from 5 to 23 years (high TG, low 
HDL-C, hypertension, abdominal obesity, MetS). Additionally, five 
of the risk-present trajectories had less decelerated growth than the 
risk-absent trajectories (i.e., differed in quadratic growth: hyperglyce-
mia, low HDL-C, abdominal obesity, MetS, inflammation). Inspection 
of the quadratic parameters indicated that the risk-present trajecto-
ries showed nonsignificant growth deceleration, reflecting continued 
steady growth, or in the case of hyperglycemia, significant accelerated 
growth (s = 0.45; P < 0.001). In contrast, all of the quadratic terms for 
the risk-absent models were significant and negative, indicating signif-
icant growth deceleration or a slowing down of growth when approach-
ing young adulthood. Thus, failure of BMI growth to decelerate when 
approaching young adulthood distinguished those with versus without 
CM risks.
Growth parameters by number of CM risks
When examining the growth parameters by number of CM risks 
(Table 4), compared with participants with no adult CM risks, those 
with one risk factor had a higher BMI at birth. No differences were 
found for linear growth from birth to 6 months by number of CM risks. 
However, compared with those with zero adult risks, those with two or 
more risks had flatter (less declining) growth from 6 months to 5 years, 
a higher 5-year BMI, faster linear growth from 5 to 23 years, and less 
decelerated growth when approaching young adulthood.
Age at growth divergence by CM risk
When examining the age at which BMI first diverged by subsequent 
CM risk, those with at least one risk factor had a significantly higher 
BMI at birth than those with zero risk factors, and those with adult ab-
dominal obesity and high TG had a higher BMI at 3 months (Table 5). 
BMI diverged significantly at 1 year for individuals with or without 
MetS, and BMI diverged at 5 years for those with or without adult hy-
perglycemia, low HDL-C, hypertension, or inflammation.
Age BMI ≥ 25 and BMI ≥ 30 by CM risk
Those with MetS in young adulthood attained BMI ≥ 25 at 12.3 years on 
average, whereas those absent MetS achieved BMI ≥ 25 approximately 
8 years later or at age 20.1 (Table 6). BMI ≥ 30 could not be estimated 
for any of the risk-absent groups, for those with inflammation or low 
HDL-C, or for those with zero or one CM risk because these individu-
als avoided BMI ≥ 30 during the study period. Those with no CM risks 
avoided BMI ≥ 25.
Sensitivity analyses
The complete case analyses testing differences in growth parameter by the 
presence of CM risks using the 549 participants who had BMI at all nine 
TABLE 2 Adjusted means of growth parameters for total 
sample at age 23 years (N = 1,000)
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TABLE 3 Adjusted means of growth parameters by cardiometabolic risk at age 23 years (N = 1,000)
 
Risk present, adjusted  
mean
Risk absent, adjusted  
mean
Unstd. effect  
estimate (SE) P
Hyperglycemia (n = 35) (n = 965)    
InterceptB 13.69* 13.76* −0.09 (0.19) 0.619
SlopeB-6 mo 1.31* 1.23* 0.004 (0.05) 0.934
Intercept6 mo 17.85* 18.07* 0.35 (0.22) 0.114
Slope6 mo-5 y 0.05 −0.12* 0.20 (0.06) 0.003
Intercept5 y 18.05* 16.78* 1.47 (0.45) 0.001
Slope5-23 y 3.17* 2.93* 0.07 (0.57) 0.883
Quadratic5-23 y 0.45* −0.13* 0.45 (0.13) 0.001
High TG (n = 143) (n = 857)    
Intercept B 13.71* 13.76* −0.07 (0.10) 0.461
SlopeB-6 mo 1.34* 1.22* 0.05 (0.03) 0.072
Intercept6 mo 18.22* 18.03* 0.18 (0.13) 0.167
Slope6 mo-5 y −0.003 −0.13* 0.10 (0.03) 0.002
Intercept5 y 17.82* 16.69* 0.90 (0.25) 0.001
Slope5-23 y 3.76* 3.07* 0.74 (0.26) 0.004
Quadratic5-23 y −0.02 −0.13* 0.05 (0.06) 0.441
Low HDL-C (n = 595) (n = 405)    
InterceptB 13.81* 13.67* 0.12 (0.07) 0.077
SlopeB-6 mo 1.23* 1.25* −0.02 (0.02) 0.348
Intercept6 mo 18.04* 18.10* −0.06 (0.09) 0.556
Slope6 mo-5 y −0.09 −0.14* 0.05 (0.02) 0.007
Intercept5 y 17.02* 16.56* 0.38 (0.15) 0.007
Slope5-23 y 3.29* 2.99* 0.31 (0.16) 0.047
Quadratic5-23 y −0.05 −0.20* 0.11 (0.04) 0.007
Hypertension (n = 93) (n = 905)    
InterceptB 13.77* 13.65* 0.16 (0.09) 0.092
SlopeB-6 mo 1.36* 1.23* 0.04 (0.04) 0.205
Intercept6 mo 18.14* 18.06* −0.18 (0.16) 0.267
Slope6 mo-5 y 0.04 −0.13* 0.20 (0.04) 0.001
Intercept5 y 18.54* 16.66* 1.88 (0.34) 0.001
Slope5-23 y 4.00* 3.09* 0.93 (0.30) 0.002
Quadratic5-23 y −0.02 −0.12* 0.10 (0.08) 0.207
Abdominal obesity (n = 312) (n = 688)    
InterceptB 13.80* 13.73* 0.002 (0.07) 0.846
SlopeB-6 mo 1.47* 1.23* 0.06 (0.02) 0.006
Intercept6 mo 18.07* 18.06* 0.05 (0.11) 0.672
Slope6 mo-5 y 0.05 −0.17* 0.20 (0.02) 0.001
Intercept5 y 18.12* 16.25* 1.92 (0.19) 0.001
Slope5-23 y 4.20* 2.70* 1.49 (0.19) 0.001
Quadratic5-23 y −0.03 −0.15* 0.13 (0.05) 0.009
Metabolic syndrome (n = 122) (n = 878)    
InterceptB 13.79* 13.75* 0.02 (0.11) 0.831
SlopeB-6 mo 1.32* 1.23* 0.03 (0.03) 0.312
Intercept6 mo 18.10* 18.06* −0.06 (0.14) 0.644
Slope6 mo-5 y 0.07 −0.13* 0.20 (0.04) 0.001
Intercept5 y 18.44* 16.59* 1.71 (0.26) 0.001
Slope5-23 y 4.22* 3.03* 1.24 (0.26) 0.001
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time points retained all but one of the significant effects found using the 
full analytic sample (Supporting Information Table S2). Additionally, the 
growth parameters and magnitude of effect estimates were highly similar. 
When analyzing the growth parameter differences by number of CM risks, 
the complete case analyses retained seven of the nine significant effects 
found using the full analytic sample (Supporting Information Table S3).
 
Risk present, adjusted  
mean
Risk absent, adjusted  
mean
Unstd. effect  
estimate (SE) P
Inflammation (n = 365) (n = 629)    
InterceptB 13.77* 13.75* 0.01 (0.07) 0.898
SlopeB-6 mo 1.21* 1.25* −0.01 (0.02) 0.745
Intercept6 mo 17.93* 18.13* −0.15 (0.10) 0.117
Slope6 mo-5 y −0.05 −0.14* 0.09 (0.02) 0.001
Intercept5 y 17.25* 16.61* 0.68 (0.16) 0.001
Slope5-23 y 3.34* 3.09* 0.20 (0.18) 0.253
Quadratic5-23 y 0.002 −0.18* 0.18 (0.04) 0.001
Models adjusted for sex, maternal BMI, maternal age, family socioeconomic status, iron supplementation from age 6 to 12 months, and duration of breastfeeding on intercept, 
slope, and quadratic.
*P < 0.001.
B, birth; unstd., unstandardized; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.
TABLE 3 (continued).
TABLE 4 Adjusted mean growth parameters by number of cardiometabolic risks at age 23 years (N = 1,000)
Number of risks 0 1 2 ≥ 3
(n = 302) 
Adj. mean
(n = 377) 
Adj. mean
P, 1 different 
from 0
(n = 199) 
Adj. mean
P, 2 different 
from 0
(n = 122) 
Adj. mean
P, ≥ 3 different 
from 0
InterceptB 13.66** 13.85** 0.017 13.70** 0.419 13.80** 0.378
SlopeB-6 mo 1.25* 1.18* 0.174 1.27* 0.404 1.23* 0.407
Intercept6 mo 18.08** 18.00** 0.673 18.16** 0.713 18.10** 0.980
Slope6 mo-5 y −0.18* −0.15* 0.085 −0.01 0.001 0.07 0.001
InterceptB 16.21** 16.40** 0.143 17.49** 0.001 18.44** 0.001
Slope5-23 y 2.65** 2.94** 0.142 3.81** 0.001 4.22** 0.001
Quadratic5-23 y −0.21** −0.13* 0.077 −0.07 0.016 0.02 0.001




TABLE 5 Age and BMI at significant growth curve divergence by presence or absence of cardiometabolic risk at age 23 years
 
Age at significant growth curve 
divergence
Adjusted BMI at age of divergence (95% CI)
PRisk present Risk absent
0 vs. 1 CM riska Birth  13.89 (13.76, 14.01)  13.68 (13.55, 13.82)  0.030
Abdominal obesity 3 mo 17.61 (17.44, 17.77) 17.36 (17.24, 17.47) 0.020
Hypertriglyceridemia 3 mo 17.68 (17.43, 17.93) 17.40 (17.30, 17.50) 0.040
MetS 1 y 18.04 (17.77, 18.32) 17.75 (17.65, 17.85) 0.048
Hyperglycemia 5 y 18.42 (17.32, 19.53) 17.02 (16.82, 17.21) 0.014
Low HDL-C 5 y 17.28 (17.03, 17.52) 16.73 (16.42, 17.04) 0.008
Hypertension 5 y 18.57 (17.97, 19.17) 16.89 (16.69, 17.09) 0.001
Inflammation 5 y 17.63 (17.30, 17.96) 16.77 (16.53, 17.01) 0.001
Models adjusted for sex, maternal BMI, maternal age, family socioeconomic status, iron supplementation from age 6 to 12 months, and duration of breastfeeding. Slight differ-
ences in BMI shown here and those shown in Tables 2, 3 and 4 are due to the absence of full information maximum likelihood specification in these estimates.
aPresence of any of the following five risk factors: hyperglycemia, hypertriglyceridemia, low HDL-C, hypertension, abdominal obesity.
CM, cardiometabolic; MetS, metabolic syndrome; HDL-C, high-density lipoprotein cholesterol.
Obesity BMI Trajectories by Cardiometabolic Risks East et al.
820    Obesity | VOLUME 28 | NUMBER 4 | APRIL 2020 www.obesityjournal.org
Discussion
In this Chilean sample, individuals who had CM risk factors showed 
different patterns of BMI growth from birth to 23 years than those with-
out CM risks. Individuals with adult CM risks had faster BMI growth 
from birth to 6 months, lower levels of expected BMI growth decline 
approaching age 5, a higher BMI at age 5, faster growth from 5 to 
23 years, and lower levels of growth deceleration approaching young 
adulthood.
Unlike studies that have found differences in growth after only 4 years 
of age by subsequent CM risk (12), current findings show that poor 
adult CM health was preceded by specific growth patterns discernable 
from 6 months onward. Indeed, the growth pattern found in the cur-
rent study reflecting faster growth from birth to 6 months and a smaller 
decline in BMI from 6 months to 5 years parallels the growth pattern 
believed to be responsible for an early age at adiposity rebound (34,35), 
which itself is a well-established risk factor for later obesity and obesi-
ty-related morbidity (34,36). The absence of a distinct BMI nadir can 
also be discerned in several of the risk-present trajectories (Figure 1). 
This constellation of early-life factors (faster growth after infancy, 
lower BMI decline approaching age 5, absence of a definitive BMI 
nadir in early childhood, higher 5-year BMI) consistently distinguished 
those who would develop CM morbidities from those who would not. It 
is widely held that rapid weight gain during infancy plays an etiological 
role in programming later-life obesity, which, in turn, is consequential 
for poor adult cardiovascular health (37,38). Current findings augment 
such work by indicating that a constellation of early-life growth factors 
is directly associated with subsequent CM morbidities.
Study findings also show that an absence of slowed growth 
when  approaching young adulthood discriminated the presence of 
several adult CM risk factors. This is consistent with findings by 
Attard et al. (5), who found that a high and increasing BMI from 13 
to 21 years was associated with elevated blood pressure and insulin 
resistance, whereas a declining adiposity trajectory was protective (5). 
Normally growing youth typically show decelerated growth during 
the transition to adulthood, as pubertal influences decline and skele-
tal growth subsides (27,39). Preventive measures would, thus, involve 
achieving graduated linear growth from early childhood onward and a 
slowing down of growth when approaching adulthood (i.e., successive 
reductions in BMI increases).
Findings also illustrate the disparity in age at which critical BMI mile-
stones are attained for those with and without adult CM risks. Avoiding 
BMI ≥ 30 prior to age 23 served as a protective factor against all of the 
CM risks studied, and individuals with zero risk factors maintained 
BMI < 25 to age 23. Such findings, in alliance with other studies (1,2), 
may be of value to clinicians and public health surveillance programs 
for identifying individuals at risk of CM risk based on age-specific BMI.
Several factors should be considered when interpreting study findings. 
All participants were born at term and had birthweights ≥ 3.0 kg as eli-
gibility criteria. Thus, premature and low–birth weight infants were 
not included, which likely affected this sample’s BMI distribution and 
growth (40) and, perhaps, the likelihood of CM risks (37). However, this 
sample restriction allowed us, by design, to control for cardiovascular 
risks associated with preterm and low birth weight. The reduced data 
available at age 5 (because of a funding cut) limited selection of the 
analytic sample. However, the analytic strategy made use of all avail-
able data, and we did not find evidence that the assumption of missing 
completely at random was violated. Moreover, a sensitivity analysis 
involving participants who had BMI at all nine study time points showed 
highly similar findings as the analytic sample, increasing confidence in 
the relations found. The absence of BMI measurements at closer age 
intervals precluded more specific estimates of growth change and lim-
ited the estimation of age at BMI growth divergence. The follow-up 
intervals between later visits were relatively large (5 years), which may 
cause biased estimations in the BMI growth curves. This study also did 
not have baseline measures of CM biomarkers or CRP. Thus, whether 
the associations found are independent of baseline levels of CM risk 
factors is not clear. Additionally, the sample was somewhat atypical 
in that approximately 60% of participants had low HDL-C in young 
adulthood. High prevalence of low HDL-C has been found in Latino 
populations (41), with some finding a genetic predisposition to dys-
lipidemia (42). Thus, findings should be considered within the racial/
ethnic and cultural (diet, lifestyle) background of study participants. 
Finally, the relatively low numbers of participants with hyperglycemia 
may have reduced statistical power to detect differences between the 
growth parameters of those with and without this risk.
Study strengths include the availability of growth data from a large 
cohort studied from birth to young adulthood. Data on weight and height 
were measured objectively by trained clinical staff from age 6 months to 
23 years, giving greater validity to the results. This study also had multiple 
objectively measured biomarkers of CM health in early adulthood, when 
disease states often first appear (43). The piecewise growth curve approach 
allowed us to determine the unique contribution of various parameters of 
growth during separate developmental periods for subsequent CM health. 
Finally, several important confounders were controlled, reducing the pos-
sibility that study findings can be attributed to such factors.
In conclusion, how BMI changes across development is important for 
CM health. Individuals with CM risks in young adulthood had unique 
TABLE 6 Mean age at BMI ≥ 25 and BMI ≥ 30 by cardiometabolic 
risk
 
Risk present Risk absent
BMI ≥ 25 BMI ≥ 30 BMI ≥ 25 BMI ≥ 30
MetS 12.3 y 17.7 y 20.1 y –
Abdominal obesity 13.0 y 18.8 y – –
Hyperglycemia 13.1 y 18.4 y 18.9 y –
Hypertension 13.2 y 19.5 y 19.4 y –
High TG 14.3 y 21.5 y 19.5 y –
Inflammation 15.9 y – 20.6 y –
Low HDL-C 16.9 y – – –
Number of CM risksa        
0 – –    
1 21.0 y –    
2 14.6 y 22.0 y    
3 13.1 y 18.9 y    
4 or 5 10.6 y 14.7 y    
Ages extrapolated from known BMI values per each cardiometabolic risk group. Dash 
indicates that average BMI for individuals with that risk did not equal or exceed 25 or 30.
aTotal number of cardiometabolic risks: hyperglycemia, hypertriglyceridemia, low 
HDL-C, hypertension, and abdominal obesity.
MetS, metabolic syndrome; TG, triglycerides; HDL-C, high-density lipoprotein choles-
terol; CM, cardiometabolic risk.
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early-life growth patterns, indicating that an early-life preventive 
approach may be useful (44). However, continued high and acceler-
ated growth from early childhood to young adulthood also consistently 
related to many CM risks, suggesting additional points of intervention 
into one’s early 20s.O
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